MEB experience: Adaptive Pathways & PRIME

Slides:



Advertisements
Similar presentations
Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
Advertisements

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Registration in Europe Current situation and future outlook Thomas K ü rner, M.D. Nippon Boehringer Ingelheim Co., Ltd.
© Safeguarding public health Expert Group on Innovation in the Regulation of Healthcare products Adaptive Licencing workshop at the Wellcome Trust October.
Susan Boynton, VP, Global Regulatory Affairs, Shire
The Statisticians Role in Pharmaceutical Development
CADTH Therapeutic Reviews
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.
CHALLENGES FOR PRAGMATIC TRIALS IN EUROPE Donna A. Messner, PhD.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Adaptive Licensing UK. Content What is adaptive licensing? Draft criteria for pilot candidate selection EMA Road Map 2015 and work programme 2012 UK perspective.
Process mapping of registration to reimbursement for new pharmaceuticals in UK.
European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Efficacy Studies (PAES)
Science is leading the revolution in targeted, personalised therapies:
Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.
Slide 1 Encouraging innovation: the regulators perspective Bringing the best to healthcare through partnership and innovation IPHA, 1 st December 2011.
China EU Pharmaceutical Forum
Gwendolyn Ryals, Look at Me Artwork from The Creative Center Janey Shin, Director, Real World Evidence Government Affairs and Market Access CADTH Symposium.
Comparative Effectiveness Research (CER) and Patient- Centered Outcomes Research (PCOR) Presentation Developed for the Academy of Managed Care Pharmacy.
Regulatory and Reimbursement Harmonization An Industry Perspective Adrian Griffin | April 2016.
I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.
PRAGMATIC Study Designs: Elderly Cancer Trials
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
Main topics Who are we at EMA and what is our regulatory experience in Parkinson’s disease (PD) Initiatives available at EMA to stimulate and support.
Off-label Use.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Prof Alex Faulkner Centre for Global Health Policy
Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) A new deal for patients, taxpayers and industry Tuesday 5 July.
Paediatric Medicine: The Paediatric Investigation Plan
A capacity building programme for patient representatives
Principles of Risk Management
EIA approval process, Management plan and Monitoring
Presentation Developed for the Academy of Managed Care Pharmacy
Speedy Assessment of Vaccines: EMA’s toolbox
MRC’s Translational Research Funding
Chrissie Fletcher, Amgen Ltd on behalf of IMI GetReal
Industry Perspective: Expanded Access Programs
Expedited Drug Approval Programs
Balancing Pre and Postmarket Requirements Different Scenarios
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
DIA Clinical Safety and Pharmacovigilance Community
The FDA Early Feasibility Study Pilot and the Innovation Pathway
Sophie Skorupka M2 AREIPS 15 novembre 2016
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
CDRH 2010 Strategic Priorities
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Hans Scheurer President Myeloma Patients Europe.
9/17/2018 Meeting local HTA requirements Challenges for the Pharma HTA Statistician Marie-Ange PAGET Project Statistician – Lilly France EFSPI meeting.
CONDITIONAL MARKETING AUTHORISATION
PRIME PRIORITY MEDICINES
New economies: Scenarios with a likelihood >50% and impact
EMA Working Groups on Committees' Operational Preparedness
African Regional Meeting on 4-5 July 2017 in Entebbe, Uganda
Helen Lee, European Commission
Presentation Developed for the Academy of Managed Care Pharmacy
Speeding access to therapies
Introduction to TransCelerate
Dr Peter Groves MD FRCP Consultant Cardiologist
Regulatory and Reimbursement Harmonization
Kaisa Immonen EPF Director of Policy
Patient Involvement in the Development and Use of Safe Medicines Introductory Section – Concepts to Consider CIOMS XI WG Second Meeting October 23-24,
1st meeting of the CIOMS Working Group XI, 19 April 2018
An introduction to EMA’s support for medicines development
EUnetHTA Assembly May 2018.
Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.
Presentation Developed for the Academy of Managed Care Pharmacy
EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation  Giulia Detela, Anthony Lodge  Molecular Therapy.
Jared Christensen and Steve Gilbert Pfizer, Inc July 29th, 2019
Presentation transcript:

MEB experience: Adaptive Pathways & PRIME Andre Elferink Dutch Medicines Evaluation Board Member Scientific Advice Working Party / PRIME oversight group Thanks for slides by Stiina Aarum, Anna F. Cerrata , B. Hiemstra, BIO Holland, P. Mol, H. Ovelgonne

Early assessment tools PRIME Adaptive Pathways Major public health interest, unmet medical need. Dedicated and reinforced support. Enable accelerated assessment. Better use of existing regulatory & procedural tools. Scientific concept of development and data generation. Iterative development with use of real-life data. Engagement with other healthcare-decision makers. Accelerated Assessment Conditional MA Major public health interest, unmet medical need. Reduce assessment time to 150 days. Unmet medical need, seriously debilitating or life-threatening disease, a rare disease or use in emergency situations. Early approval of a medicine on the basis of less complete clinical data. 20171010-AE

‘Precursors’ Conditional Marketing Authorization New Pharmacovigilance legislation Risk Management Plans Periodic Safety Update Reports Five-year renewal MAA Reproduced from Eichler et al. Clin. Pharm. Ther. 2012; 91(3): 426-437 20171010-AE

Adaptive pathways Aim: To get good medicines to the patient as soon as possible Support the selection of pathway of product development and (potential) earlier access to medicines through early dialogue involving all stakeholders (regulators, HTAs, payers, patients, learned societies.…) 20171010-AE

Adaptive pathways concept 27 February 2019 Adaptive pathways concept ”Widening of the indication" Time Final target indication in green, patient group with highest need in red 1st approval 2nd approval the sponsor could follow two strategies Simplified concept is 1st approval 20171010-AE

Conditions Prospective agreements on data requirements Including data collection after registration Including usage data, registry data Between industry, HTA and regulator Aligning HTA and licensing requirements Post licensing data to Reduce uncertainties Widen the indication Adaptive reimbursement to enforce collection of further evidence 20171010-AE

HTA/payers perspective Viability of introducing adaptive licensing depends on the assessments by HTA bodies and decision by payers Regulatory requirements for evidence need to be better harmonized with HTA requirements Allowance of - Reimbursement to rise from a initial lower level - Decreasing uncertainties of B/R - Conditions to be met - Conditions to be fulfilled 20171010-AE

Initial experience 39 products submitted as candidates 11 selected for in-depth discussion with company 4 SMEs 5 are Orphan drugs 2 are ATMP (Advanced Therapy Medicinal Products) Main reasons for rejection were: Development too advanced Limited learning potential for a pilot 20171010-AE

Criteria for selection Unmet medical need An iterative development plan (start in a well-defined subpopulation and expand, or have a Conditional Marketing Authorisation, may be surrogate endpoints and confirm) Real World Data (safety and efficacy) can be acquired to supplement Clinical Trials - RCTs / PAES / PASS / Registies / Large Data basis / Off-label use Input / commitment of all stakeholders likely 20171010-AE

Rules of the game Demonstration of a positive Benefit/Risk required. Involve all stakeholders to discuss how to demonstrate, and how to optimise requirements. Embedded within existing regulatory tools Not a new procedure, not a new approval route. A request for parallel EMA/HTA advice is expected to discuss science and requirements in depth i.e. a formal Scientific Advice letter Acceptance/rejection in the AL pilot has no inference about approval potential 20171010-AE

Challenges HTA and EMA requirements not always well aligned. After marketing authorisation reimbursement may take many years Delaying patient access HTAs do not form a homogeneous groups - Not all HTAs are interested in a scenario where reimbursements rise form am initial lower level - Some HTA’s reluctant to engage in earlier reimbursements - When uncertainties are still large - Subsidizing drug development - No chance to negotiate lower prices? - Payment by performance 20171010-AE

Challenges Companies may also be reluctant to engage in early reimbursement - Less control - Risk of low initial reimbursement - Remaining to become the final reimbursement Implementation of commitment to generate of additional data Confirmative efficacy data may be needed Confirmative efficacy data need to be generated Safety data will need to be generated After marketing authorisation there is limited use of real world data, from use of the product 20171010-AE

Solutions Talk earlier: HTA involvement at earlier stage recommended - Scientific Advice optimises resource use - Parallel HTA / EMA advice extremely helpful Confidence in the regulation increase when commitments are fulfilled 20171010-AE

Eligibility to PRIME scheme 27 February 2019 Eligibility to PRIME scheme Medicinal products of major public health interest and in particular from the viewpoint of therapeutic innovation. Potential to address to a significant extent an unmet medical need Potential game changer No satisfactory method or if method exists, bring a major therapeutic advantage Introducing new methods or improving existing ones Meaningful improvement of efficacy (impact on onset, duration, improving morbidity, mortality) Scientific justification, based on: - Rational pharmacodynamy - MOA - Proof of concept nonclinical/clinical - Preliminary efficacy - Expexted magnitude and its relevance 20171010-AE

Procedure Final recommendation Policy issues EMA & SAWP reviewers Oversight group SAWP CAT* appointed sponsor CHMP Short, lean process, involving multiple committees for robust assessment *For advanced therapies 20171010-AE

Experience one year of PRIME 27 February 2019 Experience one year of PRIME 108 requests received > 90 eligibility requests assessed > 50% from SMEs 20 granted* + Publication of report and list of products on EMA website 22% success rate 20171010-AE

70% on oncology/haematology 34% of requests for ATMPs 27 February 2019 Requests covering wide range of therapeutic areas and product type 70% on oncology/haematology 34% of requests for ATMPs Most in rare diseases Several area’s of priority: Alzheimer’s Disease Rare cancers 20171010-AE

Eligibility criteria Unmet medical need: case by case basis 27 February 2019 Eligibility criteria Unmet medical need: case by case basis Epidemiological data about the disease Justification of ‘Recognised Entity’: Diagnostic, Prevention,Treatment options, SOC Justification why the medical need is not fulfilled Life-threatening / Non-life-threatening Potential to significantly address the unmet medical need New pharmacological principle Description of observed and predicted effects, clinical relevance, added value and impact on health system Expected improvement over existing treatments if applicable Non-clinical /clinical data available Proof of principle, proof of concept non-clinical, clinical Stage in development Too early / Too advanced Further development plan for different stages of development 20171010-AE

Next steps Where are we now? 27 February 2019 Next steps Submissions Eligibility granted Kick-off mtgs Scientific advices Where are we now? Over 90 appl 19 13 8 products Written confirmation of PRIME eligibility and potential for accelerated assessment; Early CHMP Rapporteur appointment during development; Kick off meeting with multidisciplinary expertise from EU network; Enhanced scientific advice at key development milestones/decision points 20171010-AE

Early Rapporteur appointment 27 February 2019 Early rapporteur appointment Early Rapporteur appointment Opportunity for knowledge gain on the product Identification of relevant expertise and build adequate team Opportunity to influence development Very positive views on the kick-off meeting Importance of preparation and tailored agenda Facilitate interactions across committees and with EMA Timing of PRIME eligibility is critical for fruitful engagement Involvement in follow-up scientific advice and workload Need to improve follow-up communications/updates 20171010-AE

27 February 2019 Kick-off meeting To take place shortly after eligibility confirmation, at EMA Facilitate initial interaction between applicant and EU regulatory network; Discuss the overall development plan and regulatory strategy; Provide recommendation on milestones and topics for scientific advice. Multi disciplinary meeting with relevant experts from SAWP and CHMP and other committees; Introduction of product and development status by applicant; 20171010-AE

Enhanced scientific advice 27 February 2019 Enhanced scientific advice 7 products 11 SA requests following kick-off meetings Multi-stakeholder 1 EMA/HTA parallel advice 2 with patients involved All aspects covered Quality, nonclinical, clinical Scientific advice Rapporteur involvement through one of SAWP coordinator Flexibility Shorter pre-submission 3 adopted in 40 days 20171010-AE

In summary, Eligibility review: robust, short time, in writing Quality of applications received is generally high Kick-off meeting: excellent opportunity to initiate interaction and flag issues Rapporteur appointment enables early identification of potential issues Excellent collaboration across committees Iterative scientific advices with opportunity for multi- stakeholders involvement Scheme triggers discussions across product type / class 20171010-AE

Challenges Unmet medical need can not be defined unambiguously Cave: Disease slicing High expectations: PRIME is not a guarantee for success Cave: Regression to the mean Back to the ground : The work still has to be done Different expectations what should be in the clinical development plan – Clarify-Talk-Explain- future data 20171010-AE

Transparency Publication of monthly reports Broad characteristics 27 February 2019 Transparency Publication of monthly reports Broad characteristics Active substance (for eligible products only) High-level statistics 20171010-AE

Early assessment tools PRIME Adaptive Pathways Major public health interest, unmet medical need. Dedicated and reinforced support. Enable accelerated assessment. Better use of existing regulatory & procedural tools. Scientific concept of development and data generation. Iterative development with use of real-life data. Engagement with other healthcare-decision makers. Accelerated Assessment Conditional MA Major public health interest, unmet medical need. Reduce assessment time to 150 days. Unmet medical need, seriously debilitating or life-threatening disease, a rare disease or use in emergency situations. Early approval of a medicine on the basis of less complete clinical data. 20171010-AE

20171010-AE 20171010